MetLife Investment Management LLC Buys 22,334 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

MetLife Investment Management LLC grew its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 129.1% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 39,638 shares of the life sciences company’s stock after purchasing an additional 22,334 shares during the quarter. MetLife Investment Management LLC owned about 0.05% of Integra LifeSciences worth $720,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Blue Trust Inc. boosted its position in Integra LifeSciences by 100.5% during the second quarter. Blue Trust Inc. now owns 886 shares of the life sciences company’s stock valued at $26,000 after acquiring an additional 444 shares during the last quarter. CWM LLC raised its position in shares of Integra LifeSciences by 50.8% in the 2nd quarter. CWM LLC now owns 1,262 shares of the life sciences company’s stock worth $37,000 after acquiring an additional 425 shares in the last quarter. KBC Group NV lifted its stake in shares of Integra LifeSciences by 65.2% in the 3rd quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock valued at $52,000 after purchasing an additional 1,120 shares during the period. Northwest Investment Counselors LLC bought a new stake in shares of Integra LifeSciences during the 3rd quarter valued at about $73,000. Finally, Canada Pension Plan Investment Board acquired a new stake in Integra LifeSciences during the second quarter worth approximately $114,000. Institutional investors own 84.78% of the company’s stock.

Insider Buying and Selling at Integra LifeSciences

In related news, EVP Michael J. Mcbreen sold 1,700 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $24.16, for a total value of $41,072.00. Following the transaction, the executive vice president now owns 56,182 shares of the company’s stock, valued at $1,357,357.12. This represents a 2.94 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 3.10% of the stock is currently owned by company insiders.

Integra LifeSciences Stock Up 1.0 %

IART opened at $24.10 on Friday. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. Integra LifeSciences Holdings Co. has a one year low of $16.81 and a one year high of $45.42. The firm has a market capitalization of $1.86 billion, a P/E ratio of -267.75, a price-to-earnings-growth ratio of 0.82 and a beta of 1.15. The company has a fifty day moving average price of $21.44 and a 200-day moving average price of $23.88.

Integra LifeSciences (NASDAQ:IART) last announced its earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.02. The business had revenue of $380.80 million for the quarter, compared to analyst estimates of $375.81 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The company’s quarterly revenue was down .4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.76 EPS. Equities research analysts expect that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

IART has been the topic of a number of research reports. BTIG Research upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a research report on Monday, October 7th. Morgan Stanley assumed coverage on shares of Integra LifeSciences in a report on Monday, December 2nd. They set an “underweight” rating and a $20.00 price objective on the stock. Citigroup raised their target price on Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a research note on Tuesday, November 5th. Truist Financial dropped their price target on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a research note on Monday, October 14th. Finally, Bank of America reduced their price objective on Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a research note on Monday, October 7th. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the company. According to data from MarketBeat, Integra LifeSciences currently has an average rating of “Hold” and an average target price of $23.00.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.